{"url_path":"/sec/limnw/8-k/2026-06-03/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1971387/0001104659-26-070173-index.html","accession_number":"0001104659-26-070173","cik":"0001971387","ticker":"LIMN","issuer_name":"Liminatus Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1971387/0001104659-26-070173-index.html","primary_entity_key":"0001971387","primary_entity_name":"Liminatus Pharma, Inc."},"word_count":308,"has_tables":true,"body_markdown":"false\n0001971387\n\n0001971387\n\n2026-06-03\n2026-06-03\n\n0001971387\n\nus-gaap:CommonClassAMember\n\n2026-06-03\n2026-06-03\n\n0001971387\n\nus-gaap:WarrantMember\n\n2026-06-03\n2026-06-03\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of\nthe**\n\n**Securities Exchange Act of 1934**\n\n \n\n**June 3, 2026**\n\nDate of Report (Date of earliest event reported)\n\n \n\n**Liminatus Pharma, Inc.**\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n**Delaware**\n \n**001-42626**\n \n**93-2710748**\n\n(State or other jurisdiction\n \n(Commission\n \n(I.R.S. Employer\n\nof incorporation)\n \nFile Number)\n \nIdentification No.)\n\n \n\n**2251 Stern Goodman Street****, Suite E,**\n\n******Fullerton****, CA**\n \n**92833**\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(213) 273-5453**\n\n \n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act\n\n \n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which\nregistered**\n\nCommon Stock\n \nLIMN\n \nThe Nasdaq Stock Market LLC\n\nWarrants\n \nLIMNW\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging growth\ncompany x\n\n \n\nIf an emerging growth\ncompany, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}